Biological and Environmental Research Ontology

Last uploaded: December 23, 2022
Id http://purl.obolibrary.org/obo/NCIT_C1844
http://purl.obolibrary.org/obo/NCIT_C1844
Preferred Name

Temsirolimus
Definitions
An ester analog of rapamycin. Temsirolimus binds to and inhibits the mammalian target of rapamycin (mTOR), resulting in decreased expression of mRNAs necessary for cell cycle progression and arresting cells in the G1 phase of the cell cycle. mTOR is a serine/threonine kinase which plays a role in the PI3K/AKT pathway that is upregulated in some tumors.
Type http://www.w3.org/2002/07/owl#Class

All Properties

definition

An ester analog of rapamycin. Temsirolimus binds to and inhibits the mammalian target of rapamycin (mTOR), resulting in decreased expression of mRNAs necessary for cell cycle progression and arresting cells in the G1 phase of the cell cycle. mTOR is a serine/threonine kinase which plays a role in the PI3K/AKT pathway that is upregulated in some tumors.
prefLabel
Temsirolimus
label
Temsirolimus
PDQ_Closed_Trial_Search_ID
43369
code
C1844
Has_Target
prefixIRI
NCIT:C1844
in_subset
Display_Name
Temsirolimus
Preferred_Name
Temsirolimus
FDA_UNII_Code
624KN6GM2T
Contributing_Source
CTRP
FDA
Chemical_Formula
C56H87NO16
Maps_To
Temsirolimus
CAS_Registry
162635-04-3
NSC Number
683864
NCI_Drug_Dictionary_ID
43369
Legacy Concept Name
CCI-779
type
ALT_DEFINITION
A drug used to treat advanced renal cell carcinoma (a type of kidney cancer). It is also being studied in the treatment of other types of cancer. Temsirolimus blocks a protein involved in cell division, and may kill cancer cells. It is a type of rapamycin analog and a type of serine/threonine kinase inhibitor.
Is_Value_For_GDC_Property
subClassOf
PDQ_Open_Trial_Search_ID
43369
Accepted_Therapeutic_Use_For
Renal Cell Carcinoma
Advanced renal cell carcinoma
Semantic_Type
Organic Chemical
Pharmacologic Substance
UMLS_CUI
C1707080
Add comment
Add proposal
Delete Subject Author Type Created
No notes to display